EP4 Antagonist
for Immuno-Oncological therapy

AAT-007	AAT-008
Phase 1/2 ready	Phase 1/2 ready



*RQ; RQ-00015986, EP4 antagonist tool compound



Mean + SE (N = 5 or 9), *: p<0.05, **: p<0.01 versus vehicle- vehicle-treated group by Mann Whitney test

EP4 antagonists have mechanisms to cancel tumor-mediated immuno-evasions through TAM, NK cell, CTL, Treg, MDSC that are regulated by PGE_2

Model	Mice: C57BL/6J, female Cell line: mouse Lewis lung carcinoma, LL/2
Dose (Duration)	AAT-007: 400 μg/hr, SC infusion (Day 1-18) Cisplatin: 2.4 mg/kg, IP, QD (Day 1-9)
Endpoint	Tumor volume (Day 0, 4, 7, 11, 14, 18) Body weight (Day 0-9, 11, 14, 18)

AAT-007 significantly reduced tumor volume without effects on body weight

- Selective EP4 antagonist AAT-007 will be a first-in-class drug for PGE_2-mediated immuno-oncology mechanisms.
- AAT-007 could be added safely on to the present multiple drug treatment regimens in GI, lung, and breast cancers.
  - ✓ AAT-007 was safe and well tolerated in more than 900 subjects, and suggests low development risk.
- Proof of concept of AAT-007 on osteoarthritic pain is confirmed in two Phase 2a studies
- A back-up compound AAT-008 having a different chemotype is available.